Investors in Iot

Trois I Investissements Industriels Internationaux sa is an independent, family owned holding company focused on long term investments. ‍ Established in the late ‘90s in London, Trois I moved to Luxembourg in 2006, with the aim to take advantage of the country’s potential as an EU based financial platform.

The ALS Investment Fund supports and finances biotech companies that develop drugs and diagnostics for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. The ALS Investment Fund was initiated by Dutch ALS patients and is advised by a top-tier European VC firm, Life Sciences Partners. The ALS Investment Fund invests globally, but focuses on Europe and the US. The fund brings depth of disease-specific knowledge and a deep network in the space.

Humanity will always depend on medicines. Continuous innovation in the biotech sector is a given. Bringing better medicines to the market all the time. The Aescap Life Sciences and Aescap Genetics funds invest in highly innovative publicly traded biotech/life sciences companies. These companies are developing tomorrow’s medicines. Investing in Aescap funds offers the possibility to achieve excellent returns over the medium term, without taking large risks. Both funds have a focused portfolio, based on deep fundamental analyses and a strict buy and sell discipline. The Aescap funds act under the Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR) and operate under a AIFM license.

BioGeneration Ventures (BGV) is a venture capital company focused on early-stage European biotech, medtech, and diagnostics companies. With a strong track record of significant financial returns, BGV invests in healthcare innovations and builds world-class teams. The company manages over €100 million, targeting areas where scientific innovation, unmet medical needs, and the potential for significant proof of concept converge. BGV collaborates with founding teams to mature science and build companies, using its expertise to guide progress into clinical trials, leading to successful drug development and value realization for its investors.

Eyos Capital distinguishes itself as a proactive investment fund specializing in early-stage technology ventures characterized by robust intellectual property. With a hands-on approach, Eyos Capital actively supports promising companies poised for growth and innovation. Their investment strategy centers on identifying and nurturing startups with defensible technological advantages, aiming to position them as leaders in their respective fields. Eyos Capital's portfolio reflects their commitment to fostering entrepreneurial success through strategic guidance and operational support. By leveraging their expertise and network, Eyos Capital plays a pivotal role in accelerating the development and market entry of disruptive technologies, contributing to the evolution of the global tech landscape.

The Future Food Fund is an early-stage venture capital impact fund focused on investing in food and agriculture companies in North West Europe. Their primary objective is to support and accelerate the transition towards sustainable food systems. By investing in innovative startups in the food and agriculture sectors, the Future Food Fund aims to drive positive environmental and social impact while fostering economic growth. The fund targets companies that are developing groundbreaking solutions to enhance sustainability, reduce waste, and improve efficiency in food production and distribution. By providing essential capital and strategic support, the Future Food Fund empowers entrepreneurs to create scalable and impactful solutions that address the pressing challenges facing the global food system. Through their investments, they are committed to promoting a more sustainable and resilient food ecosystem for future generations.

Advent Life Sciences is a venture capital firm dedicated to investing in life sciences businesses. Focusing on innovative companies in biotechnology, pharmaceuticals, medical devices, and diagnostics, Advent Life Sciences supports the development of breakthrough technologies and therapies. By providing capital and strategic expertise, the firm helps entrepreneurs navigate the complexities of the life sciences sector, accelerating the path from research to market. Advent Life Sciences is committed to advancing healthcare solutions that improve patient outcomes and address unmet medical needs globally.

NetScientific PLC (AIM: NSCI), we are a deep tech and life sciences venture capital investment group with a diverse international portfolio of innovative companies. Based in London, United Kingdom, our focus is on identifying, investing in, and nurturing high-growth businesses both locally and globally. Our approach involves adding significant value through proactive portfolio management, guiding companies towards key value inflection points, and achieving investment returns through strategic liquidity events. We distinguish ourselves by adopting a capital-light strategy, strategically managing our balance sheet, and syndicating investments through our wholly owned VC subsidiary, EMV Capital. This lean structure allows us to effectively support a broad portfolio while maintaining flexibility and scalability. Listed on AIM, a market operated by the London Stock Exchange, we uphold our commitment to transparency and accountability in all our investment operations.

The UK Innovation & Science Seed Fund (UKI2S), managed by Future Planet Capital (FPC), we play a vital role in the UK's early-stage investment ecosystem. With over 20 years of experience, our mission is to support and nurture early-stage businesses and spinouts from inception to exit. We thrive on embracing risk as part of our strategy, working closely with our portfolio companies to provide extensive support. This includes helping them recruit top talent, establish robust governance frameworks, navigate fundraising challenges, and champion initiatives like Diversity, Equity & Inclusion (DE&I) and Environmental, Social, and Governance (ESG) practices. As stewards of impactful investing, we integrate rigorous impact metrics into our investment strategies to ensure our investments contribute not only to financial success but also to positive societal change and sustainable growth. Through our partnership with FPC, we are dedicated to fostering innovation and driving the success of pioneering tech ventures across the UK.

Syncona Partners LLP is a healthcare-focused company specializing in investing in and building global leaders in the life sciences sector. As a strategic investor, Syncona Partners LLP provides capital and operational support to life science companies, aiming to accelerate their growth and development into market leaders. They leverage their deep sector expertise and network to identify promising opportunities and nurture innovations that address significant medical challenges. Syncona Partners LLP's commitment lies in creating sustainable value and driving impactful advancements in healthcare through strategic investments and partnerships with visionary entrepreneurs and management teams.

MVM Life Science Partners, we are a specialized healthcare investment firm focused on early-stage and growth-stage companies in the life sciences sector. Founded in 1997 and headquartered in London, our firm invests globally in innovative biopharmaceuticals, medical technology, diagnostics, and digital health companies. Our approach combines deep sector expertise with strategic support to help our portfolio companies achieve their full potential. We have a strong track record of supporting groundbreaking therapies and technologies that make a significant impact on healthcare outcomes worldwide.

Phystech Ventures is an early-stage venture capital firm specializing in deep technology (deeptech) investments. With a focus on next-generation computing, life sciences, energy, mobility, and space sectors, Phystech Ventures identifies and supports startups at the forefront of technological innovation. The firm provides critical funding and strategic support to help these companies develop breakthrough technologies and scale their operations. Phystech Ventures' investment strategy is driven by a commitment to advancing transformative innovations that address global challenges and drive sustainable growth. For entrepreneurs seeking early-stage investment in deeptech sectors, Phystech Ventures offers expertise and resources to propel innovation forward.